Jiangxi Kvvit Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd., explained in plain language.
-
New drug combo targets tough pancreatic cancer gene
Disease control Not yet recruitingThis study tests a new drug called DN022150 combined with standard chemotherapy (AG) as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. About 465 adults aged 18-75 who have not had prior treatment for advanced disease will tak…
Phase: PHASE2, PHASE3 • Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New acne cream shows promise in clinical trial
Symptom relief Not yet recruitingThis study tests a new cream called KR230109 for mild to moderate acne. About 180 people aged 18 to 40 will use the cream or a placebo for 12 weeks. The goal is to see if the cream safely reduces pimples and skin bumps better than no treatment.
Phase: PHASE2 • Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New drug KR25102 tested in healthy people for first time
Knowledge-focused Not yet recruitingThis early-phase trial will test the safety and tolerability of a new drug called KR25102 in 83 healthy adults in China. Participants will receive either a single dose or multiple daily doses of the drug or a placebo. The main goal is to check for side effects and understand how …
Phase: PHASE1 • Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New schizophrenia drug candidate begins first human safety tests
Knowledge-focused Not yet recruitingThis early-stage study is testing a new drug called KR23248 in 66 healthy adults aged 18 to 45. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo. This study does not aim to treat any disease but to…
Phase: PHASE1 • Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New drug KR23343 enters first human safety trials
Knowledge-focused Not yet recruitingThis early-stage trial tests the safety and tolerability of a new drug called KR23343 in 92 healthy adults aged 18 to 45. Participants receive either the drug or a placebo, and researchers monitor for side effects, lab changes, and how the drug moves through the body. The study a…
Phase: PHASE1 • Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC